New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 9, 2014
09:19 EDTAKRXAkorn to acquire VersaPharm for $440M in cash
Akorn announced that it has entered into a definitive agreement to acquire VPI Holdings Corp., the parent company of VersaPharm Incorporated, for $440M in cash. This acquisition is expected to add $90M-$100M in annual revenues and 10c-12c in EPS, excluding new pipeline launches, deal amortization and acquisition-related expenses. Akorn intends to fund the transaction through approximately $445M in term loan borrowings. Fully committed financing for the transaction has been provided by JPMorgan Chase Bank, N.A. The acquisition will be subject to customary conditions, including termination of the waiting period under the provisions of the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended. Pending the satisfaction of such customary conditions, Akorn anticipates closing the transaction in 3Q14.
News For AKRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2015
10:00 EDTAKRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:17 EDTAKRXAkorn initiated with a Neutral at Nomura
Subscribe for More Information
September 28, 2015
07:13 EDTAKRXAkorn launches Myorisan 30 mg Capsules
Akorn announced that it has launched the recently-approved 30 mg strength of Myorisan. This launch further builds the Myorisan product portfolio that also includes 10 mg, 20 mg and 40 mg capsules.
September 25, 2015
08:00 EDTAKRXAkorn price target lowered to $41 from $50 at Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use